Objectives: Although miltefosine and paromomycin were only recently introduced to treat visceral leishmaniasis, increasing numbers of miltefosine treatment failures and occasional primary resistance to both drugs have been reported. Understanding alterations in parasite behaviour linked to drug resistance is essential to assess the propensity for emergence and spread of resistant strains, particularly since a positive effect on fitness has been reported for antimony-resistant parasites. This laboratory study compared the fitness of a drug-susceptible parent WT clinical Leishmania infantum isolate (MHOM/FR/96/LEM3323) and derived miltefosine and paromomycin drug-resistant lines that were experimentally selected at the intracellular amastigote level.
Introduction
The spread of primary antimony resistance in the Indian subcontinent has enforced the introduction of miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL). Despite the increasing number of miltefosine treatment failures, 1 clinical reports on primary miltefosine or paromomycin resistance in the field are still very scarce. 2, 3 Contrary to Leishmania donovani, miltefosine relapse isolates from Leishmania infantum-infected patients display a decreased susceptibility, which may possibly also be related to its veterinary use to treat canine leishmaniasis and L. infantum-associated HIV coinfections. Since incomplete parasite eradication is the rule in both groups, the large residual parasite reservoir will promote selection of miltefosine resistance upon repeated drug exposure. 2 -4 To support strategies concerning treatment and emergence of drug resistance, experimental selection of drug resistance can facilitate applied and fundamental 'drug resistance' research with the particular advantage that the drug-susceptible WT can be directly compared with matched derived resistant lines. While in the past resistance has mostly been selected in promastigotes, an earlier study by our group demonstrated that selection of drug resistance strongly depends on the selection protocol leading to the recommendation to use intracellular amastigotes whenever possible. 5 Although former research mainly focused on unravelling resistance mechanisms, parasite fitness must be considered a relevant factor as well, potentially influencing the spreading potential of resistant strains.
Comparison of unmatched antimony-susceptible and -resistant L. donovani strains from the Indian subcontinent indicated an enhanced fitness of antimony-resistant isolates. 6 -11 Likewise, a large-scale field study on L. donovani miltefosine cure and relapse isolates from Nepal suggested a higher in vitro infectivity of miltefosine relapse isolates. 12 Recently, evidence for increased fitness was obtained after selection of paromomycin resistance in L. donovani promastigotes. 13 The present laboratory study aimed to evaluate the impact of experimental miltefosine and paromomycin resistance on parasite fitness in an L. infantum strain isolated from an HIV coinfected patient.
14 Besides promastigote growth and metacyclogenesis, the in vitro and in vivo amastigote growth pattern and the intracellular stress response upon macrophage stimulation were compared between the drug-susceptible parent WT and the miltefosine-resistant and paromomycin-resistant derived strains. While a decreased fitness could be demonstrated for the miltefosine-resistant strain, the paromomycin-resistant isolate displayed enhanced intracellular amastigote growth and survival.
Materials and methods

Parasite strains
The L. infantum field isolate (MHOM/FR/96/LEM3323) used for the experimental selection of both miltefosine and paromomycin resistance was obtained from the Centre National de Ré fé rence des Leishmania and was isolated from a French HIV patient.
14 Promastigotes were grown in HOMEM medium (Gibco TM , Life Technologies, Ghent, Belgium) at 258C and subcultured twice weekly. Resistance was selected in intracellular amastigotes as previously described. 5 Promastigote and amastigote susceptibilities were determined as previously described 15 and are summarized in Table 1 .
Promastigote growth
The growth profile of WT, miltefosine-resistant and paromomycin-resistant promastigotes was assessed by flow cytometry (FCM). Promastigotes were diluted in PBS (Gibco TM , Life Technologies) for FCM counting, using a FACSCalibur w flow cytometer (BD Biosciences, NJ, USA) with addition of CountBright absolute counting beads (Molecular Probes TM , OR, USA) as internal standard for quantification of the exact volume analysed. To generate growth curves, promastigotes of each strain were inoculated into 5 mL of HOMEM at exactly 5×10 5 promastigotes/mL. Every 24 h, three biological replicates were quantified in duplo for up to 240 h and analysed using BD CellquestPro w software. The average promastigote density at each timepoint was calculated and used to draw the final growth curves.
Promastigote metacyclogenesis
Promastigote morphology was evaluated microscopically to assess metacyclogenesis. The promastigote flagellum/cell body length ratio was determined and promastigotes were considered metacyclic when this ratio was .2.
9 Starting from 96-h-old cultures and complementary to FCM assessment of promastigote density, a drop of promastigote suspension was Giemsa-stained every 24 h and visualized with bright field microscopy (Axiovert 200m w , Carl Zeiss) using a Zeiss Axiocam MRm w . The flagellum/cell body length ratio of ≥50 promastigotes was determined using Axiovision w software.
Promastigote infectivity
To evaluate the in vitro infectivity of WT, paromomycin-resistant and miltefosine-resistant promastigotes, their macrophage infection potential was determined. 16 Promastigotes were counted by FCM and used to infect primary mouse peritoneal macrophages at an infection ratio of 5 : 1. Live/ dead staining with TO-PRO w -3 iodide (Molecular Probes TM ) was used to correct for the variable number of dead promastigotes in the different cultures. 17 At 24 h post-infection, the macrophages were fixed with methanol, Giemsa-stained and light microscopically evaluated for level of infection. To determine the number of intracellular amastigotes per macrophage and the percentage of infected macrophages, the intracellular amastigote burden of 100 macrophages was counted in 10 randomly selected microscopic fields and used to calculate the infection index:
Infection index = total no. of amastigotes counted total no. of cells counted × total no. of macrophages
In vitro intracellular amastigote growth
To evaluate the intracellular amastigote growth of WT, paromomycinresistant and miltefosine-resistant parasites, primary peritoneal mouse macrophages were collected from female Swiss mice and seeded into 96-well plates as described previously. 18 After 24 h, promastigotes were used for infection of macrophages adopting the above metacyclogenesis criteria and following quantification by FCM. Evaluation of amastigote replication was performed every 24 h by light microscopic determination of the average infection index of ≥50 Giemsa-stained macrophages. To allow comparison between the different strains, correction for the baseline infectivity was made based on the infection ratio at 24 h post-infection For promastigote susceptibility, 10 5 log-phase promastigotes were exposed to serial dilutions of miltefosine or paromomycin for 72 h at 258C. Parasite multiplication was assessed after addition of resazurin and fluorimetric reading. For amastigote susceptibility, primary peritoneal mouse macrophages were infected with metacyclic promastigotes at an infection ratio of 15 stages per cell. Total parasite burdens were microscopically assessed on Giemsa-stained wells after 5 days of incubation. The results are expressed as percentage reductions in parasite burden compared with untreated infected controls and IC 50 s were calculated. Susceptibility values are the result of at least three independent replicates and are expressed as the mean IC 50 value+SEM. In vivo amastigote multiplication
To evaluate the in vivo infectivity and growth of each strain, 12 female BALB/c mice were infected intracardially with 2×10 7 metacyclic promastigotes. Up to 28 days post-infection, three animals per group were sacrificed at weekly intervals to determine the parasite burdens in liver, spleen and bone marrow. Amastigote burdens are expressed as Leishman-Donovan units (LDU) after microscopic quantification of the Stauber index 19 and by SYBR Green-based real-time PCR targeting the cysteine protease b (cpb) gene. Both the forward primer (5 ′ -ATG TCT TAC CAG AGC GGC G-3 ′ ) and the reverse primer (5 ′ -TCA CCC CAC GAG TTC TTG AT-3 ′ ) were purchased from Integrated DNATechnologies (Leuven, Belgium). To assess amastigote viability, a small piece of organ was placed in HOMEM medium and incubated at 258C for 2 weeks to assess promastigote back-transformation.
Intracellular amastigote stress resistance
To evaluate the capacity of intracellular amastigotes to cope with intracellular stress, infected macrophages were exposed to either Escherichia coliderived LPS and IFN-g at concentrations ranging from 0.05 to 100 ng/mL (Sigma-Aldrich, Diegem, Belgium) or S-nitroso-N-acetyl-DL-penicillamine (SNAP) (Sigma -Aldrich, Diegem, Belgium) at concentrations ranging from 0 to 800 mM for 48 h, as described previously. 7, 13, 20, 21 Macrophage stress responses were determined by microscopic assessment of the percentage amastigote burden reduction compared with unstimulated infected control cells. Since previous research on WT and paromomycinresistant strains suggested differences in host cell IL-10 production upon stimulation, 13 the production of endogenous IL-10 in the supernatant upon stimulation with 100 ng/mL LPS and 5 ng/mL IFN-g 21 was measured using ELISA (eBioscience, Vienna, Austria). 13 To correct for the variable infection ratio between strains and the associated differences in IL-10 production, the ratio of IL-10 production of stimulated infected cells was compared with unstimulated infected cells with correction for possible background IL-10 production.
Statistical analysis
All statistical analyses were performed using GraphPad Prism version 4.00 software. Statistical differences between WT and resistant parasites and between the different timepoints within one group were determined using two-way ANOVA with Bonferroni post hoc comparisons for parasite growth, parasite morphology and infection indices. Morphological and infection indices intergroup comparisons were done using the nonparametric Friedman test followed by Dunn's post hoc comparisons. Tests were considered statistically significant if P,0.05.
Ethics statement
The use of laboratory rodents was carried out in strict accordance to all mandatory guidelines (EU directives, including the Revised Directive 2010/63/EU on the Protection of Animals used for Scientific Purposes that came into force on 1 January 2013, and the Declaration of Helsinki in its latest version) and was approved by the Ethics Committee of the University of Antwerp, Belgium (UA-ECD 2010-17, 18 August 2010).
Results
Promastigote growth
No statistical differences could be demonstrated between paromomycin-resistant and WT parasites (Figure 1a) , whereas the miltefosine-resistant strain showed a significantly decreased growth pattern starting after 96 h of cultivation (Figure 1b) . All strains reached the stationary phase leading to metacyclogenesis at 144 h.
Promastigote metacyclogenesis
Although some significant differences could be observed for WT and paromomycin-resistant parasites at 144 and 168 h in favour of paromomycin-resistant parasites, the predetermined metacyclogenesis cut-off value for both strains was reached after 192 h. At that timepoint, no differences in percentage metacyclics ( 64%) were observed between WT and paromomycin-resistant parasites (Figure 2a) . The metacyclogenesis process in miltefosine-resistant parasites was much less evident ( Figure 2b ) and did not exceed 16% (data not shown). Despite several efforts to enhance metacyclogenesis and thus increase infectivity of the miltefosine-resistant strain by adaptations to the culture medium and enforced metacyclogenesis by promastigote preconditioning, 18 no increase in percentage metacyclic promastigotes could be obtained (data not shown). 
Promastigote infectivity
All strains reached their highest infectivity after 144 h of cultivation. At that timepoint, the infection indices of WT and paromomycinresistant parasites were not statistically different (Figure 3a) , whereas the infection index of the miltefosine-resistant strain was markedly lower (Figure 3b ), corresponding to its lower level of metacyclogenesis.
In vitro intracellular amastigote growth
Although an initial increase in intracellular amastigote burden was observed for all strains, paromomycin-resistant amastigotes did show a notable advantage over WT and miltefosine-resistant parasites ( Figure 4 ).
In vivo amastigote multiplication
Female BALB/c mice were infected with WT, miltefosine-resistant and paromomycin-resistant promastigotes for comparative monitoring of the amastigote multiplication ratio in the target organs. Every 7 days, three mice per strain were sacrificed and intracellular amastigote burdens in liver and spleen were determined by microscopic counting and real-time PCR. As bone marrow yields were insufficient to allow PCR, only microscopic counting was performed. Both in liver ( Figure 5a ) and spleen (Figure 5b ), paromomycin-resistant parasites reached the highest burdens while no significant differences were noted between WT and paromomycin-resistant parasites in the bone marrow ( Figure 5c ). As could be expected based on their in vitro metacyclogenesis profile, miltefosine-resistant parasites displayed significantly lower burdens in all target organs.
Intracellular amastigote stress resistance
While paromomycin-resistant parasites showed an enhanced tolerance towards nitrosative stress, no significant differences could be detected between miltefosine-resistant and WT parasites (Figure 6a) . Measurement of the endogenous IL-10 production by infected macrophages upon stimulation with LPS and IFN-g revealed significantly lower IL-10 production of miltefosine-resistant infected macrophages, whereas no significant differences Impact of drug resistance on Leishmania parasite fitness could be observed for paromomycin-resistant parasites compared with paromomycin-susceptible WT parasites (Figure 6b ).
Discussion
Miltefosine and paromomycin were approved for the treatment of VL to combat the expanding antimony resistance in the Indian subcontinent, where their use in combination therapy is now being explored as first-line option to avoid development of miltefosine or paromomycin resistance. 22, 23 Experimental selection of paromomycin-resistant L. donovani and L. infantum strains was shown to occur fairly rapidly both in vitro and in vivo 5, 24 and resistant clinical isolates have already been described. 2 The number of miltefosine treatment failures in the Indian subcontinent has increased up to 20% within only one decade of use, 1, 25 without any link between relapse and susceptibility to miltefosine. 1, 26 In L. infantum, a noticeable decrease in miltefosine susceptibility was demonstrated in vitro for relapse isolates in Brazil 4 and isolation of miltefosine-resistant isolates has been reported. 2, 3 Studying modifications associated with the resistant phenotype should provide valuable insights to monitor the emergence of drug resistance in the field. One of the phenotypic traits that recently gained a lot of interest is parasite fitness, defined as the complex interaction of numerous factors guaranteeing survival, reproduction and transmission between hosts in a given environment. 27 -29 While for most organisms the acquisition of drug resistance associates with several drawbacks, the effect of drug resistance in Leishmania on fitness remains fairly debatable and appears to be dependent on the respective drug and parasite species. 30 -34 For antimony-resistant L. donovani, various reports suggested a trend towards increased fitness enhancing the spreading potential of resistant parasites. 7 -9 Indian miltefosine relapse isolates displayed an enhanced in vitro metacyclogenesis and infectivity, 12 a promastigote-selected miltefosine-resistant L. donovani strain was shown to cope better with oxidative stress 35 and an experimentally promastigote-selected Leishmania major isolate demonstrated an increased metacyclogenesis profile. 36 However, most of these studies relied on large groups of nonmatched isolates and such findings should be interpreted with caution as the in vitro comparison of dissimilar Leishmania species or strains can be obscured by various species/strain-dependent traits. 37 Ideally, resistance characteristics should be compared between the same pre-and post-resistance strain, but as few resistant clinical isolates are currently available, obtaining such couples may prove to be extremely challenging. Hence, experimental selection of drug resistance currently remains the only way to accommodate this need. Our research group developed in vitro 2, 5 and in vivo 24 selection protocols on the intracellular amastigote stage. Compared with paromomycin, 5 selection for miltefosine resistance proved to be much more complex with only one L. infantum isolate (LEM3323) gaining a definite miltefosine-resistant phenotype on both promastigote and amastigote levels.
14 To assess the possible impact on fitness, LEM3323 and its miltefosine-and paromomycin-resistant derived counterparts were subjected to the same battery of 'virulence' assays. Although increased parasite fitness for a promastigote-selected paromomycin-resistant strain has been described, 13 no apparent benefit of paromomycin resistance could be demonstrated for the promastigote stage. When focusing on the intracellular amastigote stage, the paromomycin-resistant strain did show marked benefits over WT parasites, e.g. enhanced in vitro and in vivo amastigote replication and resistance towards macrophage-induced stress responses.
After comparison of the WT and miltefosine-resistant strain, all results suggested a decrease in parasite fitness upon acquisition of miltefosine resistance under the stated experimental conditions. This decline was evident at both the promastigote and intracellular amastigote stages and was reflected by a reduced replication potential, metacyclogenesis and stress tolerance. Although it was hypothesized that miltefosine treatment outcome could be related to the enhanced infectivity and metacyclogenesis of miltefosine relapse isolates, 12 the present study does not support this. Indeed, if relapse isolates did in fact display an enhanced infectivity, experimental selection of drug resistance would be more straightforward. The association between high infectivity and facilitated resistance development may explain why our selection protocol failed for most L. infantum and L. donovani isolates, and was successful only for the LEM3323 whose promastigotes were shown to cause massive macrophage Although the fitness decrease in miltefosine-resistant L. infantum should be confirmed in other miltefosine-resistant isolates, additional research by our group has already suggested a decline in fitness upon repeated miltefosine exposure of amastigotes in vivo as a reduced amastigote-to-promastigote transformation ability. 24 Despite the fact miltefosine resistance will certainly not be the sole factor contributing to the increasing levels of miltefosine treatment failures worldwide, 1, 4 it is encouraging to know that actual full-blown miltefosine resistance comes with a fitness cost for the parasite and may to some extent restrict extensive spread of primary resistance. With regard to the latter, parasite fitness in the vector should be explored as well. Finally, some No significant differences could be observed between WT and MIL-R parasites, while PMM-R parasites showed a significantly enhanced tolerance towards nitrosative stress inside primary peritoneal mouse macrophages (*P, 0.05). (b) Endogenous IL-10 production of infected cells stimulated with LPS and IFN-g. Statistical differences between MIL-R and WT parasites were noted (*P, 0.05), whereas IL-10 production of WT and PMM-R strains did not statistically differ. Results are expressed as mean+SEM and are based on four independent replicates run in duplicate. **P, 0.01.
